{"protocolSection": {"identificationModule": {"nctId": "NCT00289874", "orgStudyIdInfo": {"id": "0476-336"}, "secondaryIdInfos": [{"id": "2006_001"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)", "officialTitle": "A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients With Seasonal Aeroallergen Sensitivity"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-03"}, "primaryCompletionDateStruct": {"date": "2007-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-02-07", "studyFirstSubmitQcDate": "2006-02-08", "studyFirstPostDateStruct": {"date": "2006-02-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-09-09", "resultsFirstSubmitQcDate": "2010-09-10", "resultsFirstPostDateStruct": {"date": "2010-10-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-01-31", "lastUpdatePostDateStruct": {"date": "2022-02-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This is a 3-week study to evaluate FEV1 following treatment with drugs in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 421, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "montelukast", "interventionNames": ["Drug: montelukast sodium"]}, {"label": "2", "type": "PLACEBO_COMPARATOR", "description": "placebo", "interventionNames": ["Drug: Comparator: Placebo"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.", "armGroupLabels": ["1"], "otherNames": ["MK0476"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "Placebo. Up to 3 weeks of treatment", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3", "description": "Percent change from baseline in FEV1, a measure of airway function, at Week 3", "timeFrame": "Baseline and week 3"}], "secondaryOutcomes": [{"measure": "Percent Change From Baseline in Mean Daily \"as Needed\" \u03b2-agonist Use Over the 3-week Treatment Period", "description": "Percent change from baseline in average daily \u03b2-agonist use over the 3-week treatment period", "timeFrame": "Baseline and Week 3"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female patients, ages 6 to 14 years, with persistent asthma that is also active during allergy season\n* Patients must demonstrate positive skin prick tests to seasonally relevant geographic aeroallergens\n\nExclusion Criteria:\n\n* Patient cannot have any other acute or chronic pulmonary disorder", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "14 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "19484680", "type": "BACKGROUND", "citation": "Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009 May;46(4):413-20. doi: 10.1080/02770900902847727. Erratum In: J Asthma. 2009 Oct;46(8):858."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients who had unresolved symptoms and signs of an upper respiratory tract infection between Visits 1 and 2, or had evidence of active, clinically significant sinus infection within 1 week of Visit 1 or between Visits 1 and 2, or failed to meet minimum requirement for daytime asthma symptoms and daily \u03b2-agonist use were excluded.", "recruitmentDetails": "One hundred three sites in US;\n\nPrime Therapy: March 2006 to July 2007", "groups": [{"id": "FG000", "title": "Montelukast 5 mg", "description": "Montelukast 5 mg chewable tablet orally once daily at bedtime for 3 weeks."}, {"id": "FG001", "title": "Placebo", "description": "Montelukast matching-image placebo tablet orally once daily at bedtime for 3 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "203"}, {"groupId": "FG001", "numSubjects": "218"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "197"}, {"groupId": "FG001", "numSubjects": "210"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Did not meet eligibility", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Montelukast 5 mg", "description": "Montelukast 5 mg chewable tablet orally once daily at bedtime for 3 weeks."}, {"id": "BG001", "title": "Placebo", "description": "Montelukast matching-image placebo tablet orally once daily at bedtime for 3 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "203"}, {"groupId": "BG001", "value": "218"}, {"groupId": "BG002", "value": "421"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.6", "spread": "2.4"}, {"groupId": "BG001", "value": "10.7", "spread": "2.4"}, {"groupId": "BG002", "value": "10.6", "spread": "2.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "171"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "122"}, {"groupId": "BG001", "value": "128"}, {"groupId": "BG002", "value": "250"}]}]}]}, {"title": "Daily \u03b2-agonist use", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Puffs/Day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.01", "spread": "1.77"}, {"groupId": "BG001", "value": "2.72", "spread": "1.68"}, {"groupId": "BG002", "value": "2.86", "spread": "1.73"}]}]}]}, {"title": "Forced expiratory volume in 1 second (FEV1)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.81", "spread": "0.57"}, {"groupId": "BG001", "value": "1.84", "spread": "0.60"}, {"groupId": "BG002", "value": "1.83", "spread": "0.58"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3", "description": "Percent change from baseline in FEV1, a measure of airway function, at Week 3", "populationDescription": "The full analysis set population (i.e., includes all patients who had baseline and on-treatment measurements).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and week 3", "groups": [{"id": "OG000", "title": "Montelukast 5 mg", "description": "Montelukast 5 mg chewable tablet orally once daily at bedtime for 3 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Montelukast matching-image placebo tablet orally once daily at bedtime for 3 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "199"}, {"groupId": "OG001", "value": "208"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.53", "lowerLimit": "7.05", "upperLimit": "12.01"}, {"groupId": "OG001", "value": "9.15", "lowerLimit": "6.71", "upperLimit": "11.59"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Mean Daily \"as Needed\" \u03b2-agonist Use Over the 3-week Treatment Period", "description": "Percent change from baseline in average daily \u03b2-agonist use over the 3-week treatment period", "populationDescription": "The full analysis set population (i.e., includes all patients who had baseline and on-treatment measurements).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 3", "groups": [{"id": "OG000", "title": "Montelukast 5 mg", "description": "Montelukast 5 mg chewable tablet orally once daily at bedtime for 3 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Montelukast matching-image placebo tablet orally once daily at bedtime for 3 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "212"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.88", "spread": "84.75"}, {"groupId": "OG001", "value": "-12.40", "spread": "53.88"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events (AEs) were collected during the 6 week, double-blind treatment period, and up to and including 14 days after the last dose of study therapy", "description": "The number of participants listed in the SAE table (203 montelukast \\& 217 placebo) is the number that received treatment.\n\nAlthough a participant may have 2 or more AEs they are counted only once in a category. The same participant may appear in other categories.", "eventGroups": [{"id": "EG000", "title": "Montelukast 5 mg", "description": "Montelukast 5 mg chewable tablet orally once daily at bedtime for 3 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 203, "otherNumAffected": 0, "otherNumAtRisk": 203}, {"id": "EG001", "title": "Placebo", "description": "Montelukast matching-image placebo tablet orally once daily at bedtime for 3 weeks.", "seriousNumAffected": 4, "seriousNumAtRisk": 217, "otherNumAffected": 0, "otherNumAtRisk": 217}], "seriousEvents": [{"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 217}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 217}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 217}]}, {"term": "Respiratory distress", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 217}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Safety is reported in the literature."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Conduction", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}